Abstract 4416
Background
Immune checkpoint inhibitor (CPI) induced acute liver injury (ALI) is a frequently encountered toxicity occurring in up to 30% patients (pts). There is a lack of systemic evaluation of CPI induced ALI pathogenesis, clinical evolution and outcome of patients (pts).
Methods
Retrospective analysis was performed on pts with CPI induced ALI presenting to 6 UK oncology centres between 2013-17. Indices of ALI, therapy complications and outcome were recorded. ALI grading was based on Common Terminology Criteria for Adverse Events.
Results
65% (36/57) pts received ipilimumab+nivolumab (N) or pembrolizumab (P) (combo group) and 35% (21/57) P or N alone (mono group). Median therapy duration to ALI onset was 96 days in the mono and 22 days in the combo group. At presentation, all pts had acute elevations in transaminases (ALT, median 325U/L [range 155-543], ALP 111U/L [72-250]). Immunogolulins and autoantibodies were normal. One pt developed acute synthetic dysfunction without encephalopathy (Bilirubin 64umol/L, INR 1.5). 79% received steriods (mean dose 1.3mg/kg); 34% MMF. Steroid refractory ALI was treated with anti-thymocyte globulin (ATG) in 4 pts. Pathological findings (n = 6 liver biopsies) revealed lobular hepatitis and myelo-lymphoid cell infiltrate/aggregates (CD3+,CD8+,CD68+). Pts with severe, refractory (G4) ALI had significant reductions in circulating lymphocytes/monocytes. 63% (n = 35) had a temporal association between recent infection and ALI. 15% (n = 8) also received anti-TNF-a therapy for colitis. This was not associated with more severe ALI, and ALI resolved in all cases. 21% (n = 11) developed bacterial infections. Fungal sepsis (aspergillus) occurred in all ATG (n = 4) treated patients. Overall no deaths were due to liver failure. 14 pts died with 13 due to disease progression and 1 due to immunotherapy related neuropathy. All deaths due to progressive disease were in pts whose ALI peaked at G3-4. Acturial median survival was significantly lower in G3-4 (14.5 months) vs G1-2 (25 months) liver injury.
Conclusions
Our data report on the largest cohort of CPI induced ALI identifying disease evolution, markers of disease severity and strong correlation with increased morbidity and mortality.
Clinical trial identification
Legal entity responsible for the study
The Royal Marsden Hospital.
Funding
The Royal Marsden Hospital & Imperial College London.
Editorial Acknowledgement
Disclosure
J. Larkin: Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy: Elsai, BMS, MSD, GSK, Kymab, Pfizer, Novartis, Roche/Genetech, Secarna, Pierre Fabre, EUSA Pharma; Support: NIHR RM/ICR Biomedical Research Centre for Cancer. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract